Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash Flows from Operating Activities
Net income (loss)	$ 23,675	$ (4,929)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	12,325	12,009
Gain on sale of bioplastics manufacturing business	0	(1,453)
Gain on property insurance recoveries	(8,290)	0
Loss on sale of assets	38	47
Share based compensation	1,393	932
Equity method investment (earnings) loss	(10,137)	204
Distribution received from equity method investee	4,835	0
Deferred income taxes, including change in valuation allowance	1,570	(152)
Changes in operating assets and liabilities:
Restricted cash	0	12
Receivables, net	(4,851)	7,511
Inventory	476	1,542
Prepaid expenses	(331)	(129)
Refundable income taxes	78	(224)
Accounts payable	(5,928)	2,571
Accounts payable to affiliate, net	2,129	(2,804)
Accrued expenses	(373)	3,264
Deferred credits	174	(208)
Accrued retirement health and life insurance benefits, pension obligations, and other noncurrent liabilities	(699)	(876)
Other	(272)	(17)
Net cash provided by operating activities	15,812	17,300
Cash Flows from Investing Activities
Additions to property and equipment	(6,953)	(6,208)
Proceeds from sale of bioplastics manufacturing business	0	2,797
Proceeds from property insurance recoveries	8,450	0
Proceeds from sale of property and other	5	0
Net cash provided by (used in) investing activities	1,502	(3,411)
Cash Flows from Financing Activities
Payment of dividends	(907)	(916)
Purchase of treasury stock	(672)	(540)
Loan fees incurred with borrowings	(66)	0
Principal payments on long-term debt	(1,555)	(1,683)
Proceeds from revolving credit facility	62,146	95,512
Principal payments on revolving credit facility	(73,476)	(103,405)
Net cash used in financing activities	(14,530)	(11,032)
Increase in cash	2,784	2,857
Cash, beginning of year	2,857	0
Cash, end of year	$ 5,641	$ 2,857